ENANTA PHARMACEUTICALS, INC Payments of Debt Issuance Costs
ENANTA PHARMACEUTICALS, INC (ENTA) reported Payments of Debt Issuance Costs of $0 for the 12-month period ending 2025-09-30, per its 10-K filed 2025-11-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2025-11-19
- ENANTA PHARMACEUTICALS, INC payments of debt issuance costs for the quarter ending 2024-09-30 was $0.00.
- ENANTA PHARMACEUTICALS, INC payments of debt issuance costs for the quarter ending 2023-09-30 was $0.00.
- ENANTA PHARMACEUTICALS, INC payments of debt issuance costs for the quarter ending 2022-09-30 was $0.00.
- ENANTA PHARMACEUTICALS, INC payments of debt issuance costs for fiscal 2025 was $0.00.
- ENANTA PHARMACEUTICALS, INC payments of debt issuance costs for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- ENANTA PHARMACEUTICALS, INC payments of debt issuance costs for fiscal 2023 was $325.00K.
- ENANTA PHARMACEUTICALS, INC payments of debt issuance costs for fiscal 2022 was $0.00.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|
| 2025-09-30 | $0.00 10-K · filed 2025-11-19 | ||
| 2024-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19 | $0.00 10-K · filed 2025-11-19 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-07 | ||
| 2023-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19 | $325.00K 10-K · filed 2025-11-19 | |
| 2023-06-30 | $325.00K 10-Q · filed 2024-08-07 | ||
| 2022-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-27 | $0.00 10-K · filed 2024-11-27 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-08 | ||
| 2021-09-30 | $0.00 10-K · filed 2023-11-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |